Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors
Academic Article
Overview
MeSH Major
Antineoplastic Agents
Central Nervous System Neoplasms
Clinical Trials, Phase I as Topic
Research Design
abstract
Patients with HGG who meet standard eligibility criteria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic drugs with favorable preclinical rationale and pharmacokinetic properties in this population.
